描述了作为活化氨基酸衍生物的氮杂内酯的第一次催化不对称共轭加成反应向烯酮的发展和进一步发展。第一代方法是从孤立的氮杂内酯开始的,而第二代方法中的氮杂内酯可以从外消旋的N开始原位生成。苯甲酰化氨基酸。第三个进化阶段可以利用外消旋未保护的α-氨基酸直接形成高度对映体富集和非对映体纯的带掩蔽季铵氨基酸产物,并带有一个附加的叔立体中心。通过使用稳固的平面手性bis-Pd催化剂,布朗斯台德酸(HOAc或BzOH; Ac =乙酰基,Bz =苯甲酰基)和布朗斯台德碱(NaOAc),通过协同活化来实现逐步经济转型。特别是第二代和第三代方法提供了快速而多样化的途径,可从廉价的散装化学品中获得生物学上令人感兴趣的非天然季氨基酸衍生物。这样,可以以非对映体纯形式制备高度对映体富集的无环α-氨基酸,α-烷基脯氨酸和α-烷基焦谷氨酸衍生物。此外,
描述了作为活化氨基酸衍生物的氮杂内酯的第一次催化不对称共轭加成反应向烯酮的发展和进一步发展。第一代方法是从孤立的氮杂内酯开始的,而第二代方法中的氮杂内酯可以从外消旋的N开始原位生成。苯甲酰化氨基酸。第三个进化阶段可以利用外消旋未保护的α-氨基酸直接形成高度对映体富集和非对映体纯的带掩蔽季铵氨基酸产物,并带有一个附加的叔立体中心。通过使用稳固的平面手性bis-Pd催化剂,布朗斯台德酸(HOAc或BzOH; Ac =乙酰基,Bz =苯甲酰基)和布朗斯台德碱(NaOAc),通过协同活化来实现逐步经济转型。特别是第二代和第三代方法提供了快速而多样化的途径,可从廉价的散装化学品中获得生物学上令人感兴趣的非天然季氨基酸衍生物。这样,可以以非对映体纯形式制备高度对映体富集的无环α-氨基酸,α-烷基脯氨酸和α-烷基焦谷氨酸衍生物。此外,
DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
申请人:Molteni Valentina
公开号:US20090012094A1
公开(公告)日:2009-01-08
Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
申请人:Molteni Valentina
公开号:US20070149538A1
公开(公告)日:2007-06-28
Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.